LT2654750T - Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai - Google Patents

Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai

Info

Publication number
LT2654750T
LT2654750T LTEP11805210.9T LT11805210T LT2654750T LT 2654750 T LT2654750 T LT 2654750T LT 11805210 T LT11805210 T LT 11805210T LT 2654750 T LT2654750 T LT 2654750T
Authority
LT
Lithuania
Prior art keywords
kinase inhibitors
casein kinase
pyridine compounds
fused pyridine
novel fused
Prior art date
Application number
LTEP11805210.9T
Other languages
English (en)
Inventor
Todd W. Butler
Ramalakshmi Y. CHANDRASEKARAN
Scot R. MENTE
Chakrapani Subramanyam
Travis T. Wager
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of LT2654750T publication Critical patent/LT2654750T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
LTEP11805210.9T 2010-12-20 2011-12-06 Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai LT2654750T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425213P 2010-12-20 2010-12-20
PCT/IB2011/055489 WO2012085721A1 (en) 2010-12-20 2011-12-06 Novel fused pyridine compounds as casein kinase inhibitors

Publications (1)

Publication Number Publication Date
LT2654750T true LT2654750T (lt) 2017-05-10

Family

ID=45446116

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17151228.8T LT3181133T (lt) 2010-12-20 2011-12-06 Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai
LTEP11805210.9T LT2654750T (lt) 2010-12-20 2011-12-06 Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP17151228.8T LT3181133T (lt) 2010-12-20 2011-12-06 Nauji kondensuoti piridino junginiai, kaip kazeino kinazės inhibitoriai

Country Status (24)

Country Link
US (1) US8536164B2 (lt)
EP (2) EP3181133B1 (lt)
JP (2) JP5684923B2 (lt)
KR (1) KR101590236B1 (lt)
CN (1) CN103260622B (lt)
AR (1) AR084412A1 (lt)
AU (1) AU2011346733C1 (lt)
CA (1) CA2819961C (lt)
CY (2) CY1118772T1 (lt)
DK (2) DK3181133T3 (lt)
ES (2) ES2623387T3 (lt)
HK (1) HK1188145A1 (lt)
HR (2) HRP20170484T1 (lt)
HU (2) HUE032405T2 (lt)
IL (1) IL226948A (lt)
LT (2) LT3181133T (lt)
MX (1) MX338551B (lt)
PL (2) PL2654750T3 (lt)
PT (2) PT2654750T (lt)
RS (2) RS59098B1 (lt)
SG (1) SG190802A1 (lt)
SI (2) SI3181133T1 (lt)
WO (1) WO2012085721A1 (lt)
ZA (1) ZA201303453B (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2493876E (pt) * 2009-10-28 2014-03-20 Pfizer Derivados de imidazol como inibidores de caseína cinase
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
JP6283688B2 (ja) * 2012-12-21 2018-02-21 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カゼインキナーゼ1d/e阻害剤としての新規なピラゾール置換のイミダゾピラジン
WO2015163446A1 (ja) * 2014-04-25 2015-10-29 協和発酵キリン株式会社 イミダゾール化合物の製造方法
JP2017222576A (ja) * 2014-10-31 2017-12-21 石原産業株式会社 有害生物防除剤
CN107365315A (zh) * 2016-05-11 2017-11-21 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
TW202112368A (zh) * 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
EP4126878A1 (en) * 2020-03-27 2023-02-08 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
CN111808102B (zh) * 2020-08-03 2021-12-31 南通大学 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法
US20230339900A1 (en) * 2020-09-17 2023-10-26 Janssen Pharmaceutica Nv Casein kinase 1 delta modulators
JP2023541465A (ja) * 2020-09-17 2023-10-02 ヤンセン ファーマシューティカ エヌ.ベー. カゼインキナーゼ1デルタモジュレーター
WO2022127755A1 (en) * 2020-12-15 2022-06-23 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
WO2023241552A1 (en) * 2022-06-14 2023-12-21 Gritscience Biopharmaceuticals Co., Ltd Salt and/or crystal form for compounds as casein kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
TR200000235T2 (tr) * 1997-05-22 2000-05-22 G.D. Searle &Co. p38 kinaz inhibitörleri olarak ikame edilmiş pirazoller.
AR029423A1 (es) * 1999-12-21 2003-06-25 Sugen Inc Compuesto derivado de pirrolo-[pirimidin o piridin]-6-ona, metodo de preparacion de dichos compuestos, composiciones farmaceuticas que los comprenden, un metodo para regular, modular o inhibir la actividad de la proteina quinasa y un metodo de tratar o prevenir una enfermedad de mamiferos
US20070010523A1 (en) 2005-06-22 2007-01-11 Chemocentryx, Inc. Azaindazole compounds and methods of use
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
PT2493876E (pt) * 2009-10-28 2014-03-20 Pfizer Derivados de imidazol como inibidores de caseína cinase

Also Published As

Publication number Publication date
CA2819961C (en) 2015-08-18
CY1118772T1 (el) 2017-07-12
EP3181133A1 (en) 2017-06-21
CN103260622B (zh) 2015-05-13
EP2654750B1 (en) 2017-03-08
KR101590236B1 (ko) 2016-01-29
CA2819961A1 (en) 2012-06-28
SI3181133T1 (sl) 2019-10-30
AU2011346733C1 (en) 2015-12-24
PT3181133T (pt) 2019-09-16
HRP20170484T1 (hr) 2017-06-02
PL3181133T3 (pl) 2019-12-31
JP5876596B2 (ja) 2016-03-02
DK3181133T3 (da) 2019-08-26
AU2011346733B2 (en) 2015-08-13
CY1122062T1 (el) 2020-11-25
ES2623387T3 (es) 2017-07-11
WO2012085721A1 (en) 2012-06-28
SG190802A1 (en) 2013-07-31
US20120157440A1 (en) 2012-06-21
SI2654750T1 (sl) 2017-04-26
ES2744099T3 (es) 2020-02-21
HK1188145A1 (en) 2014-04-25
RS59098B1 (sr) 2019-09-30
AU2011346733A1 (en) 2013-07-18
HUE047089T2 (hu) 2020-04-28
US8536164B2 (en) 2013-09-17
PT2654750T (pt) 2017-05-04
AR084412A1 (es) 2013-05-15
EP2654750A1 (en) 2013-10-30
MX2013005833A (es) 2013-07-05
LT3181133T (lt) 2019-09-25
JP5684923B2 (ja) 2015-03-18
KR20130121126A (ko) 2013-11-05
RS55897B1 (sr) 2017-08-31
JP2015107992A (ja) 2015-06-11
ZA201303453B (en) 2014-07-30
EP3181133B1 (en) 2019-07-24
CN103260622A (zh) 2013-08-21
JP2014503544A (ja) 2014-02-13
HRP20191469T1 (hr) 2019-11-29
HUE032405T2 (en) 2017-09-28
PL2654750T3 (pl) 2017-07-31
IL226948A (en) 2017-04-30
MX338551B (es) 2016-04-20
DK2654750T3 (en) 2017-05-01

Similar Documents

Publication Publication Date Title
HK1188145A1 (en) Novel fused pyridine compounds as casein kinase inhibitors
HK1192247A1 (zh) 作為激酶抑制劑的雜環化合物
HK1199203A1 (en) Kinase inhibitor polymorphs
ZA201303801B (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
EP2552208A4 (en) IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
PL2531501T3 (pl) Inhibitory kinazy 1 regulującej sygnał apoptotyczny
EP2552214A4 (en) PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2552211A4 (en) INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
ZA201208489B (en) Fused bicyclic kinase inhibitors
EP2685992A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
HK1201271A1 (en) Kinase inhibitor polymorphs
EP2758387A4 (en) Pyridine compounds as kinase inhibitors
ZA201401416B (en) Novel rock kinase inhibitors
HK1209316A1 (en) Substituted picolinamide kinase inhibitors
GB201109162D0 (en) Casein kinase 1Delta (CK1Delta) inhibitors
GB201021161D0 (en) Casein kinase 1delta (CK1Delta) inhibitors
GB201102024D0 (en) Novel heterocyclic compounds 3
GB201101821D0 (en) Novel heterocyclic compounds 1
GB201101822D0 (en) Novel heterocyclic compounds 2
GB201101823D0 (en) Novel heterocyclic compounds 4